INMB · INmune Bio, Inc.

INmune Bio continued its clinical-stage focus in 2025, with revenue growing to $50K from $14K in 2024, signaling early commercialization traction for CORDStrom after the prior year's single UK customer sale of MSCs. This 257% increase provides initial validation of the commercial transition, though it remains modest relative to the company's R&D-driven expense base.

Looking forward, the company expects persistent and growing losses as it advances product candidates through R&D, clinical activities, and regulatory processes. Potential delays in commercial launch, pricing, reimbursement, manufacturing scale-up, or market acceptance pose risks even post-approval. Regulatory constraints, such as EU prohibitions on physician inducements, and pricing pressures could further impact prospects. Additional capital remains critical, though availability on reasonable terms is uncertain, underscoring the need for prudent resource allocation amid the pivot toward CORDStrom momentum.